Key clinical point: DMD treatment in this commercial population was low.
Major finding: Among MS patients followed for 2 years, 43% had no claim for a DMD.
Study details: A retrospective administrative claims study of 63,946 patients with MS.
Disclosures: Funding for the study was provided by EMD Serono, a Merck company. Dr. Phillips is an employee of the company.
Phillips A et al. ACTRIMS FORUM 2019, Abstract 001.